Löhr J M, Faissner R, Findeisen P, Neumaier M
Klinische Kooperationseinheit für Molekulare Gastroenterologie (dkfz E180), II. Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg.
Internist (Berl). 2006 Jun;47 Suppl 1:S40-8. doi: 10.1007/s00108-006-1634-7.
Ductal pancreatic adenocarcinoma is a dismal disease, having the worst prognosis of all solid tumors. While genomics and transcriptomics have provided a wealth of data, no contribution has been made to clinical medicine in terms of diagnostic or prognostic markers. Hope lies in yet another novel technology, proteomics. Conceptually, proteomics bears the advantage of incorporating both posttranslational modifications as well as host factors. This is thought to be important in factors influencing survival such as chemoresistance. This tutorial review discusses the state of the art in pancreatic cancer proteomics in light of technical developments. At this moment, proteomics is still at the beginning in clinical application. First results, however, suggest some hope for the development of a new understanding of the molecular biology in pancreatic cancer yielding into very specific markers of disease or allowing a rational and individualized therapy.
胰腺导管腺癌是一种预后极差的疾病，在所有实体瘤中预后最差。虽然基因组学和转录组学已经提供了大量数据，但在诊断或预后标志物方面对临床医学没有做出贡献。希望寄托在另一项新技术——蛋白质组学上。从概念上讲，蛋白质组学具有纳入翻译后修饰以及宿主因素的优势。这被认为在影响生存的因素如化疗耐药性方面很重要。本综述根据技术发展情况讨论了胰腺癌蛋白质组学的现状。目前，蛋白质组学在临床应用中仍处于起步阶段。然而，初步结果为深入了解胰腺癌的分子生物学带来了希望，有望产生非常特异的疾病标志物或实现合理的个体化治疗。
